SOTIO, a Czech-based biotech firm, has completed the acquisition of Cytune Pharma, a firm developing inrterleukin (IL)-15 based therapies for the treatment of cancer.
The biotech-firm will continue the development of lead program SO-C101 (RLI-15) and will also initiate first-in-human clinical trials in 2019.
In future, all Cytune projects will be the part of SOTIOs pipeline.
Through this deal, Cytune will become an important part of SOTIOs projects in the biotech sector and will also collaborate with its Accord Research.
The biotech major is likely to start the first-in-human study with SO-C101 in selected European countries and the USA early next year.
A major part of this study will be the combination of immune checkpoint inhibitors.
We are excited about the completion of the acquisition and welcome Cytune to the PPF Group. Cytune and SOTIO have been closely and very successfully collaborating over the course of the last few years and we very much look forward to initiating the first clinical trials with SO-C101 in a few months, said SOTIO chief utive Radek Spisek.
Im proud that our products, originating from INSERM and the University of Nantes and supported by Bpifrance and Atlanpole Biotherapies, hold the potential to lead to new therapeutic options for the treatment of cancer patients. Such IL-2/IL-15RÎ²Î³ agonists represent a new and very promising class of drugs in the immune-oncology segment as they have shown to re-induce responses in patients after failure to checkpoint inhibitors treatment, said David Bechard, President and COO, Cytune.